The Technical Analyst
ProKidney Corp. [PROK]
Exchange: NASDAQ Capital Market Sector: Healthcare Industry: Biotechnology
ProKidney Corp. Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
-2.21% $2.19
/ 7 mai 2024 @ 09:36
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 503.59 mill |
| EPS: | -0.580 |
| P/E: | -3.78 |
| Earnings Date: | May 03, 2024 |
| SharesOutstanding: | 229.92 mill |
| Avg Daily Volume: | 0.751 mill |
| RATING 2024-05-06 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Neutral | |
| Return On Asset: | Sell | |
| DE: | Strong Sell | |
| P/E: | Sell | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | |||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -3.78 | sector: PE 0 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE -3.78 | industry: PE 0 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$0.911 (-58.40%) $-1.279 |
| Date: 2024-05-07 |
| Expected Trading Range (DAY) |
|---|
|
$ 1.989 - 2.49 ( +/- 11.21%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-18 | Weber Darin J. | Sell | 800 | Class A Ordinary Shares |
| 2024-04-22 | Weber Darin J. | Sell | 16 438 | Class A Ordinary Shares |
| 2024-04-16 | Weber Darin J. | Sell | 17 238 | Class A Ordinary Shares |
| 2024-04-01 | Weber Darin J. | Sell | 300 | Class A Ordinary Shares |
| 2024-04-12 | Weber Darin J. | Sell | 84 103 | Class A Ordinary Shares |
| INSIDER POWER |
|---|
| -30.62 |
| Last 96 transactions |
| Buy: 21 807 248 | Sell: 30 162 499 |
Forecast:
11:15 - $2.24
Live Trading Signals (every 1 min)
Forecast
1: 09:45 - $2.20
Forecast 2: 10:35 - $2.22
Forecast 3: 11:15 - $2.24
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $2.19 (-2.21% ) |
| Volume | 0.0130 mill |
| Avg. Vol. | 0.751 mill |
| % of Avg. Vol | 1.732 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For PROK
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:34 | buy | $1.265 | N/A | Active |
|---|
PROK
ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
Latest Press Releases
2024-03-25 06:05:00 - Press Release
Prokidney Announces Key Leadership Appointments Strengthening Clinical And Technical Operations
Dr. ulrich ernst joins as executive vice president of technical operations with a deep background and expertise in process development and manufacturing of cell therapies
2024-03-21 19:49:00 - Press Release
Prokidney Reports Full Year 2023 Financial Results And Recent Corporate Highlights
Winston-salem, n.c., march 21, 2024 (globe newswire) -- prokidney corp. (nasdaq: prok) (“prokidney” or the “company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (ckd), today announced financial results for the year ended december 31, 2023.
2024-02-29 16:05:00 - Press Release
Prokidney To Participate In Jefferies Biotech On The Bay Summit
Winston-salem, n.c., feb. 29, 2024 (globe newswire) -- prokidney corp. (nasdaq: prok) (“prokidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (ckd), today announced that senior members of the management team will be participating in the jefferies biotech on the bay summit being held in miami on march 12 – 13, 2024.
2023-11-30 06:05:00 - Press Release
Prokidney Appoints Nikhil Pereira-kamath, Mba, As Chief Business Officer
Former ceo of africa healthcare network brings extensive understanding of kidney disease to prokidney former ceo of africa healthcare network brings extensive understanding of kidney disease to prokidney
2023-11-21 06:05:00 - Press Release
Prokidney To Participate In A Fireside Chat At The Upcoming Evercore Isi 6th Annual Healthconx Conference
Winston-salem, n.c, nov. 21, 2023 (globe newswire) -- prokidney corp. (nasdaq: prok) (“prokidney” or the “company”), a leading late clinical-stage cellular therapeutics company focused on preserving kidney function in patients living with chronic kidney disease (ckd), today announced that management will be participating in a fireside chat at the 6th annual evercore isi healthconx conference being held in miami, florida on november 28-30, 2023.
Latest News
2023-11-24 06:40:00 - InvestorPlace
7 Penny Stocks With Low Floats and High Short Interest
There are many ways to approach penny stocks, but one that has gained popularity in recent years focuses on stocks in this category that are prime candidates for a “short squeeze.” A typical short squeeze candidate has a high level of short interest, or percentage of outstanding float sold short.
2023-11-16 16:40:27 - Seeking Alpha
ProKidney Corp. (PROK) Q3 2023 Earnings Call Transcript
ProKidney Corp. (NASDAQ:PROK ) Q3 2023 Results Conference Call November 14, 2023 8:00 AM ET Company Participants Dr. Glenn Schulman - SVP of IR Pablo Legorreta - Chairman of Board Dr. Tim Bertram - Co-Founder and Member of Scientific Advisory Board Dr. Bruce Culleton - Chief Executive Officer Conference Call Participants Yigal Nochomovitz - Citi Justin Zelin - BTIG Jonathan Miller - Evercore Jason Gerberry - Bank of America Operator Good morning, ladies and gentlemen, and welcome to the ProKidney Corporate Update Conference Call. At this time, all lines are in a listen-only mode.
2023-11-16 11:17:57 - Zacks Investment Research
After Plunging -37.39% in 4 Weeks, Here's Why the Trend Might Reverse for ProKidney Corp. (PROK)
The heavy selling pressure might have exhausted for ProKidney Corp. (PROK) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
2023-10-17 11:19:33 - Zacks Investment Research
ProKidney Corp. (PROK) Loses -54.93% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
ProKidney Corp. (PROK) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
2023-10-16 14:50:41 - InvestorPlace
Is Chamath Palihapitiya Giving Up on ProKidney (PROK) Stock?
Shares of ProKidney (NASDAQ: PROK ) are in the green today, despite recent sales from special purpose acquisition company (SPAC) sponsor Chamath Palihapitiya. Back in July of 2022, ProKidney agreed to merge with Social Capital Suvretta Holdings Corp III in a business combination valued at $2.64 billion.
2023-10-12 15:05:23 - The Motley Fool
Why Shares of ProKidney Were Dropping Thursday
ProKidney focuses on therapies to treat chronic kidney disease (CKD). One of its top shareholders sold roughly $1.23 million worth of company stock.
2023-09-05 06:05:00 - GlobeNewsWire
ProKidney to Participate in Fireside Chat at the Morgan Stanley Global Healthcare Conference
WINSTON-SALEM, N.C., Sept. 05, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on preserving kidney function in patients suffering from chronic kidney disease (CKD), today announced that Dr. Tim Bertram, Chief Executive Officer, will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference, being held in New York, NY from September 11 – 14, 2023.
2023-09-04 08:24:18 - Finbold
Short squeeze alert for September 4th: Two stocks with potential to skyrocket
A short squeeze is when traders who heavily short a stock start to cover their short positions by buying back the stock. This increases demand for the stock, and it pushes the price higher, forcing other short sellers to buy back.
2023-08-31 10:33:45 - InvestorPlace
3 Biotech Stocks Due for a Massive Short Squeeze
Here's a look at 3 biotech short squeeze candidates. For investors looking for short-term gains, technical analysis provides key insights on potential entry and exit points.
2023-05-04 06:05:00 - GlobeNewsWire
ProKidney to Present at the BofA Securities Health Care Conference 2023
WINSTON-SALEM, N.C., May 04, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced that Dr. Tim Bertram, Chief Executive Officer, will present at the BofA Securities Health Care Conference 2023 in Las Vegas, NV on Tuesday, May 9, 2023, at 4:20 PM PDT (7:20 PM EDT).